1022 Evaluation of Potential Virologic Resistance in HBV Polymerase Among Subjects With Persistent Viremia Following Up to 144 Weeks of Therapy With Tenofovir Df

Snow–Lampart, Andrea; Chappell, Brandi J; Sorbel, J.; Borroto–Esoda, Katyna; Miller, Michael G.

doi:10.1016/s0168-8278(10)61023-9

Search citation statements

Order By: Relevance

Paper Sections

Select...

Similar or Contrasting Cases In The Literature1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2011

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,5 We found no evidence of emtricitabine/tenofovir resistance mutations, which is consistent with findings in studies where patients with ongoing HBV viremia, despite therapeutic plasma tenofovir levels, have no demonstrable drug associated mutations to these drugs. 9 Our patient has also been immunotolerant to HBV, as evidenced by normal transaminase levels until the last several months. Further work-up will be needed to determine the extent of the liver damage.…”

Section: Similar or Contrasting Cases In The Literaturementioning

confidence: 58%

HIV–HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance

Schirmer¹,

Winters

Holodniy

2011

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Similar or Contrasting Cases In The Literaturementioning

confidence: 58%

HIV–HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance

Schirmer¹,

Winters

Holodniy

2011

Journal of Clinical Virology

View full text Add to dashboard Cite

Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B

Jenh¹,

Pham

2010

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir. Tenofovir is available orally as tenofovir disoproxil fumarate (ester pro-drug of tenofovir) and inhibits replication of both hepatitis B virus and HIV-1. Owing to its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir has replaced adefovir as a first-line oral monotherapy option in the treatment of CHB in the 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines. Additionally, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other CHB therapies including lamivudine and adefovir.

show abstract

1022 Evaluation of Potential Virologic Resistance in HBV Polymerase Among Subjects With Persistent Viremia Following Up to 144 Weeks of Therapy With Tenofovir Df

Cited by 2 publications

References 0 publications

HIV–HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance

HIV–HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance

Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B

Contact Info

Product

Resources

About